Ventyx Biosciences, Inc.
A biopharmaceutical company developing new treatments for inflammatory and autoimmune diseases. The company is developing oral TYK2 inhibitors for immune diseases such as psoriasis, psoriatic arthritis, and Crohn's disease, oral medications for ulcerative colitis, and NLRP3 inhibitors for systemic inflammatory diseases such as cardiovascular disease, liver disease, and rheumatism. Based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | California |
Employees | 74 |
Founded | 2018 |
Financials | |
|---|---|
Market Capitalization | 180.48M |
Revenue | |
Operating Income | -207.21M |
Operating Margin | |
Net Income | -192.60M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 5092 / 5373 |
Sector : Healthcare | 1034 / 1144 |
Industry : Biotechnology | 566 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 3701 / 5565 |
Sector : Healthcare | 613 / 1182 |
Industry : Biotechnology | 312 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 5074 / 5436 |
Sector : Healthcare | 1041 / 1164 |
Industry : Biotechnology | 575 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4214 / 5330 |
Sector : Healthcare | 705 / 1174 |
Industry : Biotechnology | 298 / 667 |